$TOVX
Theriva Biologics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000141057822003167 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.420M $2.670M $2.486M
YoY Change -2.65% 104.91% 115.61%
% of Gross Profit
Research & Development $3.070M $2.570M $2.779M
YoY Change 10.47% 30.32% 183.57%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $13.00K
YoY Change 130.77% 11.11% -59.38%
% of Gross Profit
Operating Expenses $7.330M $5.014M $5.265M
YoY Change 39.22% 53.1% 146.95%
Operating Profit -$5.014M
YoY Change 53.1%
Interest Expense $310.0K $160.0K $2.000K
YoY Change 15400.0% 7900.0%
% of Operating Profit
Other Income/Expense, Net $161.0K
YoY Change 7950.0%
Pretax Income -$7.020M -$4.825M -$5.263M
YoY Change 33.38% 47.42% 146.86%
Income Tax -$1.430M -$335.0K
% Of Pretax Income
Net Earnings -$5.590M -$4.853M -$5.263M
YoY Change 6.21% 48.27% 149.55%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33
Diluted Earnings Per Share -$0.35 -$0.33 -$398.2K
COMMON SHARES
Basic Shares Outstanding 15.84M 15.84M 132.0M
Diluted Shares Outstanding 15.84M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.79M $50.49M $67.33M
YoY Change -37.93% -30.01% 981.18%
Cash & Equivalents $41.80M $50.49M $67.33M
Short-Term Investments
Other Short-Term Assets $3.500M $2.030M $1.533M
YoY Change 128.31% 42.76% 23.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables $87.00K $214.0K $0.00
Total Short-Term Assets $45.52M $52.73M $68.86M
YoY Change -33.89% -28.31% 767.89%
LONG-TERM ASSETS
Property, Plant & Equipment $345.0K $262.0K $101.0K
YoY Change 241.58% 127.83% -41.95%
Goodwill $5.525M $4.254M $0.00
YoY Change
Intangibles $19.15M $20.09M
YoY Change
Long-Term Investments
YoY Change
Other Assets $120.0K $110.0K $23.00K
YoY Change 421.74% 378.26% 0.0%
Total Long-Term Assets $26.34M $25.96M $1.507M
YoY Change 1647.91% 1560.1% 216.6%
TOTAL ASSETS
Total Short-Term Assets $45.52M $52.73M $68.86M
Total Long-Term Assets $26.34M $25.96M $1.507M
Total Assets $71.86M $78.70M $70.37M
YoY Change 2.13% 4.76% 736.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $915.0K $770.0K $524.0K
YoY Change 74.62% -38.65% -40.86%
Accrued Expenses $1.496M $1.411M $1.928M
YoY Change -22.41% 39.84% 108.43%
Deferred Revenue
YoY Change
Short-Term Debt $57.00K $52.00K $0.00
YoY Change
Long-Term Debt Due $60.00K $50.00K
YoY Change
Total Short-Term Liabilities $7.060M $13.19M $3.554M
YoY Change 98.65% 317.47% 19.82%
LONG-TERM LIABILITIES
Long-Term Debt $220.0K $200.0K $0.00
YoY Change
Other Long-Term Liabilities $8.400M $3.660M $1.403M
YoY Change 498.72% 161.24% 654.3%
Total Long-Term Liabilities $8.620M $3.860M $1.403M
YoY Change 514.4% 175.52% 654.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.060M $13.19M $3.554M
Total Long-Term Liabilities $8.620M $3.860M $1.403M
Total Liabilities $17.30M $20.55M $4.957M
YoY Change 248.94% 350.47% 57.27%
SHAREHOLDERS EQUITY
Retained Earnings -$291.0M -$285.4M -$271.3M
YoY Change 7.26% 7.28% 9.35%
Common Stock $343.8M $343.6M $336.7M
YoY Change 2.1% 1.26% 39.79%
Preferred Stock
YoY Change
Treasury Stock (at cost) $288.0K
YoY Change
Treasury Stock Shares $720.0K
Shareholders Equity $54.56M $56.39M $65.41M
YoY Change
Total Liabilities & Shareholders Equity $71.86M $78.70M $70.37M
YoY Change 2.13% 4.76% 736.68%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$5.590M -$4.853M -$5.263M
YoY Change 6.21% 48.27% 149.55%
Depreciation, Depletion And Amortization $30.00K $20.00K $13.00K
YoY Change 130.77% 11.11% -59.38%
Cash From Operating Activities -$5.370M -$4.450M -$4.810M
YoY Change 11.64% 106.4% 53.58%
INVESTING ACTIVITIES
Capital Expenditures $90.00K $20.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$90.00K -$20.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.290M 2.740M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.370M -4.450M -4.810M
Cash From Investing Activities -90.00K -20.00K 0.000
Cash From Financing Activities -3.290M 2.740M 0.000
Net Change In Cash -8.750M -1.730M -4.810M
YoY Change 81.91% -19.76% -2266.67%
FREE CASH FLOW
Cash From Operating Activities -$5.370M -$4.450M -$4.810M
Capital Expenditures $90.00K $20.00K $0.00
Free Cash Flow -$5.460M -$4.470M -$4.810M
YoY Change 13.51% 107.33% 53.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15844061
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13204254
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15176927
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11844863
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
syn Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12584
dei Entity Registrant Name
EntityRegistrantName
THERIVA BIOLOGICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address Country
EntityAddressCountry
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
417-4364
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TOVX
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 us-gaap Assets Current
AssetsCurrent
52731000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15844061
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50490000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67325000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2241000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68858000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
262000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
90000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1246000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1383000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20089000
CY2022Q3 us-gaap Goodwill
Goodwill
4254000
CY2022Q3 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2021Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2022Q3 us-gaap Assets
Assets
78695000
CY2021Q4 us-gaap Assets
Assets
70365000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
770000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
524000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1411000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1928000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1319000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
9483000
CY2022Q3 us-gaap Loans Payable Current
LoansPayableCurrent
52000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
157000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13192000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3554000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2419000
CY2022Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
202000
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3489000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1244000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1403000
CY2022Q3 us-gaap Liabilities
Liabilities
20546000
CY2021Q4 us-gaap Liabilities
Liabilities
4957000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15844294
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15844061
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13204487
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13204254
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
90000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78695000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
336679000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2844000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-285378000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271284000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
55415000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
16000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343621000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70365000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2444000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1303000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5599000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3988000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2570000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1972000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8652000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5021000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
5014000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
3275000
us-gaap Operating Expenses
OperatingExpenses
14251000
us-gaap Operating Expenses
OperatingExpenses
9009000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5014000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3275000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14251000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9009000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-40000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
170000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
197000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
161000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
157000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-4853000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-3273000
us-gaap Profit Loss
ProfitLoss
-14094000
us-gaap Profit Loss
ProfitLoss
-9005000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4853000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3273000
us-gaap Net Income Loss
NetIncomeLoss
-14094000
us-gaap Net Income Loss
NetIncomeLoss
-9004000
CY2022Q3 syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5193000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15844061
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11844863
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13204254
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15176927
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3273000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14434000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17926000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-4853000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-3273000
us-gaap Profit Loss
ProfitLoss
-14094000
us-gaap Profit Loss
ProfitLoss
-9005000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1527000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2844000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6380000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3273000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16938000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-9005000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6380000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3273000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16938000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9004000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
112000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6599000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-181000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4273000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68027000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
113000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
1498000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4968000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61674000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
121000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
1527000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4853000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
55415000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7540000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
101000
CY2021Q1 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
65960000
CY2021Q1 syn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
8042000
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
24000
CY2021Q1 syn Adjustments To Effect Of Preferred Stock Price
AdjustmentsToEffectOfPreferredStockPrice
0
CY2021Q1 syn Conversion Of Series Preferred Stock To Common Stock
ConversionOfSeriesPreferredStockToCommonStock
12822000
CY2021Q1 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76824000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2536000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
102000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3195000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73731000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
102000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3273000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70560000
us-gaap Profit Loss
ProfitLoss
-14094000
us-gaap Profit Loss
ProfitLoss
-9005000
us-gaap Share Based Compensation
ShareBasedCompensation
346000
us-gaap Share Based Compensation
ShareBasedCompensation
305000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-257000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
74000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-780000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-285000
syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
137000
syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
123000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-504000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
368000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-326000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
85000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
271000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-147000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-127000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-168000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13714000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8080000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
3863000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
syn Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
417000
syn Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4305000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1376000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65960000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8042000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1358000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74002000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-84000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16661000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
65908000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6227000
syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
340000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50580000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72135000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50490000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72135000
syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
0
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50580000
syn Deferred Tax Liability Measurement Period Adjustment
DeferredTaxLiabilityMeasurementPeriodAdjustment
0
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72135000
syn Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
12158000
syn Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
0
syn Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
6599000
syn Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
0
syn Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
417000
syn Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
0
syn Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
-884000
syn Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
0
syn In Process Research And Development Measurement Period Adjustment
InProcessResearchAndDevelopmentMeasurementPeriodAdjustment
810000
syn In Process Research And Development Measurement Period Adjustment
InProcessResearchAndDevelopmentMeasurementPeriodAdjustment
0
syn Deferred Tax Liability Measurement Period Adjustment
DeferredTaxLiabilityMeasurementPeriodAdjustment
202000
syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
0
syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
7402000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1270000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2477000
syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
0
syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
1497000
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
0
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
24000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
158437840
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15844061
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
syn Number Of Intangible Assets Generated As Result Of Acquisition
NumberOfIntangibleAssetsGeneratedAsResultOfAcquisition
2
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q3 syn Measurement Period Adjustment
MeasurementPeriodAdjustment
810000
CY2022Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
202000
CY2022Q3 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
607000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
5800000
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
21700000
CY2022Q2 us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Financial Liabilities
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities
277000
CY2021Q4 us-gaap Goodwill
Goodwill
0
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
5765000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
884000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
627000
CY2022Q3 us-gaap Goodwill
Goodwill
4254000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
12200000
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-226000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-257000
CY2022Q3 syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q3 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1169000
CY2021Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
458000
CY2022Q3 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
573000
CY2021Q4 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
0
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
214000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2022Q3 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
180000
CY2021Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
272000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
105000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
803000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2241000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1097000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
932000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
835000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
831000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
262000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2022Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
99000
CY2022Q3 syn Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1411000
CY2022Q3 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
773000
CY2021Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
696000
CY2022Q3 syn Accrued Vendor Payments
AccruedVendorPayments
366000
CY2021Q4 syn Accrued Vendor Payments
AccruedVendorPayments
1028000
CY2022Q3 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
173000
CY2021Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
204000
CY2021Q4 syn Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1928000
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1067000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
886000
CY2022Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
146000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
92000
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
106000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1319000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
2.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0265
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3M18D
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
395000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.90
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.90
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.90
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.22
syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2020 syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
900000
CY2020Q4 syn Over Allotment Option Period
OverAllotmentOptionPeriod
P45D
CY2021Q1 syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1165575
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q3 syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.24
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1800072
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.24
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
1165575
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
1.24
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2018Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
71
CY2018Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5200000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14400000
syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2022Q3 syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3300000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17900000
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0
CY2021Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0
CY2022Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7900000
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
899677
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 syn Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
20000
CY2022Q3 syn Votes Relating To Preferred Stock
VotesRelatingToPreferredStock
1549295
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2018Q4 syn Over Allotment Option Period
OverAllotmentOptionPeriod
P45D
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.90
CY2020Q4 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
880000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.90
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2022Q3 syn Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
899677
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
66000000.0
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2022Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
90000
CY2022Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
52000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
202000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
52000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
57000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
56000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
46000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
28000
CY2022Q3 syn Long Term Debt Maturity Year Six
LongTermDebtMaturityYearSix
15000
CY2022Q3 syn Long Term Debt.
LongTermDebt.
254000
syn Number Of Operating Lease For Facilities
NumberOfOperatingLeaseForFacilities
2
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
syn Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
CY2022Q3 syn Percentage Of Funds To Be Borrowed By Company
PercentageOfFundsToBeBorrowedByCompany
8.5
syn Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
163000
us-gaap Operating Lease Cost
OperatingLeaseCost
409000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
77000
us-gaap Operating Lease Cost
OperatingLeaseCost
195000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
142000
us-gaap Operating Lease Payments
OperatingLeasePayments
399000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
80000
us-gaap Operating Lease Payments
OperatingLeasePayments
240000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
27000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
327000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
337000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
347000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
357000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
368000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1763000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
362000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1401000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
157000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1244000

Files In Submission

Name View Source Status
0001410578-22-003167-index-headers.html Edgar Link pending
0001410578-22-003167-index.html Edgar Link pending
0001410578-22-003167.txt Edgar Link pending
0001410578-22-003167-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220930.xsd Edgar Link pending
tmb-20220930x10q.htm Edgar Link pending
tmb-20220930x10q001.jpg Edgar Link pending
tmb-20220930xex31d1.htm Edgar Link pending
tmb-20220930xex32d1.htm Edgar Link pending
tmb-20220930x10q_htm.xml Edgar Link completed
tmb-20220930_cal.xml Edgar Link unprocessable
tmb-20220930_lab.xml Edgar Link unprocessable
tmb-20220930_def.xml Edgar Link unprocessable
tmb-20220930_pre.xml Edgar Link unprocessable